Icariin and icaritin enhance the sensitivity of resistant liver, breast, ovarian, and osteosarcoma to first-line chemotherapy drugs (doxorubicin, tamoxifen and cisplatin) by inhibiting P-gp, MDR1 or MRP1 [714, 715]. This evidence concerns the gene PGP and osteosarcoma.